PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Clinical trials for PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to fix Chemo's lingering side effect in cancer survivors
Disease control Recruiting nowThis study tests whether adding all-trans retinoic acid to romiplostim N01 can better raise platelet counts in adults who have low platelets after finishing chemotherapy for gastrointestinal cancers. About 220 participants will receive either the combo or romiplostim alone for 12…
Matched conditions: PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo aims to fix chemo side effect in cancer survivors
Disease control Recruiting nowThis study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…
Matched conditions: PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC